Liquid Biopsy
New Challenges in the era of Immunotherapy and Precision Oncology
- 1st Edition - November 3, 2022
- Imprint: Academic Press
- Editors: Antonio Russo, Ettore Capoluongo, Antonio Galvano, Antonio Giordano
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 2 7 0 3 - 9
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 2 7 1 1 - 4
Liquid Biopsy: New Challenges in the era of Immunotherapy and Precision Oncology aims to describe links between cancer, precision oncology, and liquid biopsy, focusing on their… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteLiquid Biopsy: New Challenges in the era of Immunotherapy and Precision Oncology aims to describe links between cancer, precision oncology, and liquid biopsy, focusing on their participation to immunotherapy management. The book provides updated information on the main applications of liquid biopsy and immunotherapy as well as interesting aspects useful for planning basic and translational research activities. It helps readers understand the central aspects of precision medicine in oncology, including the use of new generation technologies for translational and diagnostic settings and the main clinical trials in this area that may be useful during their research.
The book is a valuable source for cancer researchers, oncologists and other members of the medical and biomedical field who are interested in learning more about recent developments in liquid biopsy and its relationship with precision medicine and immunotherapy.
The book is a valuable source for cancer researchers, oncologists and other members of the medical and biomedical field who are interested in learning more about recent developments in liquid biopsy and its relationship with precision medicine and immunotherapy.
- Presents a “highlights section” in every chapter to help readers summarize the main aspects discussed
- Encompasses case reports to guide the reader on applying what they read in their clinical practice
- Includes several tables and figures specially created for the book to illustrate the meaning of what is expressed in the text
Cancer researchers, medical scientists, clinicians, graduate students
- Cover image
- Title page
- Table of Contents
- Copyright
- List of contributors
- Preface
- Chapter 1. What is precision medicine in oncology?
- Abstract
- 1.1 Introduction: what does precision medicine mean?
- 1.2 The role of biomarkers in precision medicine
- 1.3 Classification of biomarkers
- 1.4 The rationale for the definition of tumor mutational burden
- 1.5 Collecting samples for mutational analysis: tissue or liquid biopsy?
- 1.6 Pragmatical aspects of precision medicine: how to build it?
- 1.7 Precision medicine and clinical trials: is there something different?
- 1.8 Precision medicine in oncology: what is its “area-of-application”?
- 1.9 Pharmacogenomics and precision medicine
- 1.10 Determination of programmed death-ligand 1 expression in non-small cell lung carcinoma in order to choose patients eligible for immunotherapy
- 1.11 Through the concept of synthetic lethality: poly ADP-ribose polymerases-inhibitors and precision medicine
- 1.12 Colorectal cancer e microsatellite instability
- 1.13 Conclusions
- Conflict of interest statement
- References
- Chapter 2. Liquid biopsy: a right tool in a right context?
- Abstract
- Subchapter 2.1. Liquid biopsy in NSCLC
- Learning objectives
- 2.1.1 Expert opinion
- 2.1.2 Key points
- 2.1.3 Summary of clinical recommendations
- Acknowledgments
- Further reading
- Subchapter 2.2. The role of mutated ctDNA in nonmalignant lesions: challenging aspects in liquid biopsy implementation
- Learning objectives
- 2.2.1 Expert opinion
- 2.2.2 Key points
- Acknowledgments
- Further reading
- Chapter 3. Liquid biopsy: new challenges in the era of immunotherapy and precision oncology NGS and the other faces of molecular biology
- Abstract
- 3.1 Tissue or liquid biopsy?
- 3.2 Next-generation sequencing for identification of gene alterations in liquid biopsy
- 3.3 Liquid biopsy in monitoring response to therapy
- 3.4 Expert opinion
- 3.5 Key points
- 3.6 Hints for deeper insight
- References
- Further reading
- Chapter 4. Current clinically validated applications of liquid biopsy
- Abstract
- 4.1 Circulating tumor DNA in advanced non-small cell lung cancer
- 4.2 Emerging clinical applications of liquid biopsy
- 4.3 Liquid biopsy application in clinical research
- 4.4 Key points
- Acknowledgments
- References
- Chapter 5. Liquid biopsy and immunotherapy: is all that glitter gold?
- Abstract
- 5.1 Background: the need for predictive biomarkers for patient selection
- Abbreviations
- Key points
- Expert opinion
- Acknowledgments
- References
- Chapter 6. Which technology performs better? From sample volume to extraction and molecular profiling
- Abstract
- Subchapter 6.1. Molecular profiling
- Learning objectives
- 6.1.1 Expert opinion
- 6.1.2 Key points
- Further reading
- Subchapter 6.2. Biological fluid withdrawal: how much sample volume is enough?
- Learning objectives
- 6.2.1 Introduction
- 6.2.2 Other body fluids used in liquid biopsy-based assays
- 6.2.3 Key points
- Further reading
- Subchapter 6.3. Methods for cf/ct DNA isolation
- Learning objectives
- 6.3.1 Key points
- Acknowledgments
- Further reading
- Subchapter 6.4. CTC and exosome: from the enrichment to the characterization
- Learning objectives
- 6.4.1 Introduction
- 6.4.2 Exosome enrichment
- 6.4.3 Exosomes characterization
- 6.4.4 Circulating tumor cells enrichment methods
- 6.4.5 Key points
- Further reading
- Subchapter 6.5. Circulating RNAs (miRNA, lncRNA, etc): from the enrichment to the characterization
- Learning objectives
- 6.5.1 Introduction
- 6.5.2 Housekeeping RNAs
- 6.5.3 Regulatory ncRNAs
- 6.5.4 Key points
- 6.5.5 Expert opinion
- Acknowledgments
- Further reading
- Subchapter 6.6. Cell-free/circulating tumor DNA profiling: from next-generation sequencing-based to digital polymerase chain reaction-based methods
- Learning objectives
- 6.6.1 Introduction
- 6.6.2 Targeted next-generation sequencing methods
- 6.6.3 Untargeted next-generation sequencing methods
- 6.6.4 Droplet digital polymerase chain reaction methods
- 6.6.5 Key points
- 6.6.6 Expert opinion
- Acknowledgments
- Subchapter 6.7. Standardization and quality assurance in liquid biopsy testing
- Learning objectives
- 6.7.1 Introduction
- 6.7.2 Cell-free DNA in liquid biopsy: preanalytical limitations
- 6.7.3 The preanalytical phase of circulating tumor cells analysis
- 6.7.4 The preanalytical phase of exosomes analysis
- 6.7.5 Standardization initiatives and ISO/CEN/external quality assessment development in liquid biopsy
- 6.7.6 Key points
- 6.7.7 Expert opinion
- Acknowledgments
- Further reading
- Chapter 7. Early detection screening: myth or reality?
- Abstract
- References
- Chapter 8. Molecular tumor board
- Abstract
- Expert opinion
- Key points
- Acknowledgments
- References
- Chapter 9. Future perspectives
- Abstract
- Acknowledgments
- References
- Glossary
- Index
- Edition: 1
- Published: November 3, 2022
- No. of pages (Paperback): 250
- No. of pages (eBook): 250
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780128227039
- eBook ISBN: 9780128227114
AR
Antonio Russo
Antonio Russo, MD, is a Full Professor of Medical Oncology at DICHIRONS Dept, University of Palermo (Italy). He is President of COMU (the Italian National Board of University Medical Oncologists), Italy. He is author of more than 350 publications in peer-reviewed journals. He focused his studies on liquid biopsy since 2003.
Affiliations and expertise
Medical Oncology Director, Department of Oncology - A.O.U.P. "P. Giaccone" University Hospital, ItalyEC
Ettore Capoluongo
Ettore Capoluongo, PhD, is a Full Professor of Clinical Biochemistry and Clinical Molecular Biology and, Head of Clinical Pathology Dept. Cannizzaro Hospital, Catania (Italy). He has published over 270 publications in peer-reviewed journals.
Affiliations and expertise
Department of Molecular Medicine and Medical Biotechnologies, Universita Federico II - CEINGE, Biotecnologie Avanzate, ItalyAG
Antonio Galvano
Antonio Galvano, MD, PhD is an Associate Professor of Medical Oncology at DICHIRONS Dept, University of Palermo (Italy). He has focused his research efforts on liquid biopsies for cancer prognosis and treatment.
Affiliations and expertise
Professor of Surgery, Oncology and Stomatology, Universita degli Studi di Palermo | UNIPA · Department of Surgery, Oncology and StomaLiquid Biopsy: tology, ItalyAG
Antonio Giordano
Antonio Giordano, MD, PhD, is the Director at the Sbarro Institute at Temple University, Philadelphia (USA) and a Full Professor at University of Siena, Italy. He is best known for his discovery of cyclins, CDK9, CDK10 and Rb2/p130. He is the president and founder of the Sbarro Health Research Organization (SHRO), Philadelphia (USA). He has published over 600 publications in peer-reviewed journals.
Affiliations and expertise
Director of Sbarro Institute for Cancer Research and Molecular Medicine, and Center of Biotechnology College of Science and Technology, Temple University, USARead Liquid Biopsy on ScienceDirect